Articles > Devices & Technology

Older Adults with Type 1 Diabetes Benefited from CGM Use: Study

The results of the WISDM study, recently presented at the ADA’s 79th Scientific Sessions, examined the effectiveness of wearing CGMs versus blood glucose monitors on hypoglycemia.

Cam Med’s Bandage-Thin Evopump Makes Progress in Development

The company has gained big backers for its innovative insulin pump design, including JDRF and Johnson & Johnson, and the device is currently being tested on pigs.

Dexcom CEO Kevin Sayer Talks G6, G7 and the Future of Continuous Glucose Monitoring

T1D Exchange Glu sat down with the president and CEO of Dexcom to discuss his company’s plans and the future of continuous glucose monitoring.

According to data released by Medtronic, those CGM users who used the artificial intelligence app stayed between 70 mg/dL and 180 mg/dL 4% longer than those CGM users who didn’t.

DreaMed Leverages Big Data to Improve Treatment for People with Diabetes

A profile of an Israeli medical tech company which aims to help clinicians and patients interpret data from diabetes devices.

Medtronic Launches In-Home Trial of 780G, As Well as Clinical Trial of new CGM sensor.

The 780G trial will evaluate an automated basal-and-bolus insulin delivery system. We provide enrollment info for both trials.

Better Depression Screening and Higher CGM Adoption: Measuring Data at Diabetes Clinics

At the American Diabetes Association Scientific Sessions, the T1D Exchange Quality Improvement Collaborative shared early findings from efforts to standardize data collection and improve care at pediatric diabetes clinics.

Tidepool Announces Partnership with Medtronic and Dexcom for Tidepool Loop

The goal is to create an interoperable automated insulin delivery device compatible with the Dexcom G6, as well as a future MiniMed pump or future Omnipod pump.

FDA Approves Eversense CGM for Non-Adjunctive Use

Users of the CGM soon will no longer need fingersticks to verify blood glucose readings before making management decisions.

Dual-Hormone iLet Bionic Pancreas Leads to Improvement in Glucose Levels in Small, In-Home Trial

Beta Bionics and Zealand Pharma announce positive Phase 2 results of a small trial of the dual-hormone system ahead of the ADA Scientific Sessions.